A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
A phase 1/2 trial of Disitamab vedotin in advanced solid tumours, run by Pfizer, active and no longer recruiting.
Overview
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer is a phase 1/2 interventional study registered as NCT06966453 by Pfizer, with 74 participants enrolled, started 2025-06-30 and due to reach its primary completion in 2027-10-25. Interventions recorded: Disitamab vedotin.
Similar pages
not linked directly; found by shared links- TrialA Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
Shares Disitamab vedotin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTo Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Shares Disitamab vedotin and the tag pipeline.